Dare Bioscience
DARE
37 hedge funds and large institutions have $33.9M invested in Dare Bioscience in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 5 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 38 → 37 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
25% less capital invested
Capital invested by funds: $45.4M → $33.9M (-$11.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.34M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$766K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$202K |
| 4 |
Bank of New York Mellon
New York
|
+$67.2K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$64.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.02M |
| 2 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.74M |
| 3 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$68.9K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$45K |
| 5 |
Millennium Management
New York
|
-$35.7K |
DARE Hedge Fund Activity: Q4 2015 in Review
37 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q4 2015, worth a combined $33.9M — down 25% from $45.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DARE and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 13 added.
The largest buyer was Granahan Investment Management, adding an estimated $1.34M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.02M sold.
- 37 institutional investors held Dare Bioscience (DARE) as of Q4 2015, down from 38 in Q3 2015.
- Funds reported $33.9M of Dare Bioscience stock for Q4 2015, down 25% quarter-over-quarter.
- 4 funds opened new Dare Bioscience positions in Q4 2015 and 5 closed out, a net change of -1 holder.
- The largest Dare Bioscience buyer in Q4 2015 was Granahan Investment Management, an estimated $1.34M added.
- The largest Dare Bioscience seller in Q4 2015 was Cormorant Asset Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q4 2015.